Seizing Aduhelm precedent, Biogen, Eisai get the ball rolling on another accelerated Alzheimer's approval

Biogen — together with partners at Eisai — will be the first to breeze down that Alzheimer’s trail it blazed with the FDA’s historic and controversial accelerated approval of Aduhelm.